Journal Article

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial

Doshi, Sagar, Shepherd, Bridget, MacDonald, Thomas M, Rogers, Amy, Finlayson, Jim, Grieve, JW Kerr, Johnson, Richard, Mackintosh, Anne, Rooke, Evelien D, Guthrie, Greg, Newby, David, Barnes, Lawrence, Taggar, Jaspal S, Ahmed, Husnat, Dryburgh, Moira, Jennings, Claudine, Duce, Suzanne L, Fuat, Ahmet, Shakir, Saad, Struthers, Allan D, Preiss, David, McEleny, Paul, Pigazzani, Filippo, Nadir, Adnan, Khan, Sohail, Snedden, Gordon, Doney, Alexander SF, Zutis, Kris, Ford, Ian, Isaard, Emma, Dawson, Jesse, Wetherall, Kirsty, Ralston, Stuart, Long, Susan, Macleod, Mary Joan, Wei, Li, Denvir, Martin, Trevelyan, Jasper, Avery, Anthony J, Barr, Rebecca J, Eddleston, Michael, Randall, Marc, Greenlaw, Nicola, Weir, Christopher, Caulfield, Mark, Petrie, Colin, Wilson, Adam, Dumbleton, Jennifer S, Sims, Don, Aziz, Jane, Krishnan, Kailash, McCormack, Terry, Morar, Monique, Furnace, Jacqueline, Ham, Sharon, Routledge, Helen, Townend, Jonathan N, Kerr, Claire, Weir, Robin, Brighton, Tom, Hawkey, Christopher J, Begg, Alan G, Walker, Andrew, Ritchie, Lewis D, Sharma, Raj, Mackenzie, Isla S, Wilson, Robbie, Boyle, Sarah, Brown, Morris, Arthur

2022

Overview

Allopurinol is a urate-lowering therapy used to treat patients with gout. Previous studies have shown that allopurinol has positive effects on several cardiovascular parameters. The ALL-HEART study aimed to determine whether allopurinol therapy improves major cardiovascular outcomes in patients with ischaemic heart disease. ALL-HEART was a multicentre, prospective, randomised, open-label, blinded-endpoint trial done in 18 regional centres in England and Scotland, with patients recruited from 424 primary care practices. Eligible patients were aged 60 years or older, with ischaemic heart disease but no history of gout. Participants were randomly assigned (1:1), using a central web-based randomisation system accessed via a web-based application or an interactive voice response system, to receive oral allopurinol up-titrated to a dose of 600 mg daily (300 mg daily in participants with moderate renal impairment at baseline) or to continue usual care. The primary outcome was the composite cardiovascular endpoint of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death. The hazard ratio (allopurinol vs usual care) in a Cox proportional hazards model was assessed for superiority in a modified intention-to-treat analysis (excluding randomly assigned patients later found to have met one of the exclusion criteria). The safety analysis population included all patients in the modified intention-to-treat usual care group and those who took at least one dose of randomised medication in the allopurinol group. This study is registered with the EU Clinical Trials Register, EudraCT 2013-003559-39, and ISRCTN, ISRCTN32017426. Between Feb 7, 2014, and Oct 2, 2017, 5937 participants were enrolled and then randomly assigned to receive allopurinol or usual care. After exclusion of 216 patients after randomisation, 5721 participants (mean age 72·0 years [SD 6·8], 4321 [75·5%] males, and 5676 [99·2%] white) were included in the modified intention-to-treat population, with 2853 in the allopurinol group and 2868 in the usual care group. Mean follow-up time in the study was 4·8 years (1·5). There was no evidence of a difference between the randomised treatment groups in the rates of the primary endpoint. 314 (11·0%) participants in the allopurinol group (2·47 events per 100 patient-years) and 325 (11·3%) in the usual care group (2·37 events per 100 patient-years) had a primary endpoint (hazard ratio [HR] 1·04 [95% CI 0·89–1·21], p=0·65). 288 (10·1%) participants in the allopurinol group and 303 (10·6%) participants in the usual care group died from any cause (HR 1·02 [95% CI 0·87–1·20], p=0·77). In this large, randomised clinical trial in patients aged 60 years or older with ischaemic heart disease but no history of gout, there was no difference in the primary outcome of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death between participants randomised to allopurinol therapy and those randomised to usual care. UK National Institute for Health and Care Research.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: Aged / Allopurinol / Allopurinol - therapeutic use / Angina pectoris / Blood pressure / Blood tests / Cardiovascular disease / Cardiovascular diseases / Cerebral infarction / Clinical trials / Coronary artery disease / Coronary Artery Disease - drug therapy / Coronary vessels / Creatinine / Disease prevention / Electrolytes / Fatalities / Female / Gout / Gout - drug therapy / Hazard assessment / Health care / Health hazards / Heart attacks / Heart diseases / Humans / Interactive systems / Ischemia / Male / Myocardial infarction / Myocardial Infarction - drug therapy / Myocardial Ischemia - drug therapy / Observational studies / Oxidative stress / Patients / Primary care / Prospective Studies / Randomization / Renal function / Rheumatism / Statistical models / Stroke / Stroke - drug therapy / Therapy / Treatment Outcome / United Kingdom / Uric Acid / Vein & artery diseases